BCMA (B-cell maturation antigen) is a cell surface receptor predominantly expressed on plasma cells and overexpressed in malignant plasma cells. In parallel, the expression of soluble BCMA is found to be elevated in the serum of patients with multiple myeloma (MM) and leukemia. Data has shown that soluble BCMA is a valid biomarker for prognosis, treatment response, and patient monitoring. Consequently, measurement of soluble BCMA is key for patient stratification during clinical trials and monitoring treatment efficacy.
CellCarta offers an off-the-shelf assay to quantify and monitor soluble BCMA in plasma samples.
No need for invasive bone marrow biopsies or aspirates. Quantification of soluble BCMA from easily available plasma samples is achievable using mass spectrometry and the assay can be performed under GCLP and CAP/CLIA environments.
Our targeted approach using MRM provides specificity, sensitivity, precision, and accuracy, all of which are critical parameters for biomarker measurement ultimately used in predicting disease, treatment decisions, and real-time assessment of disease progression.
Our scientists developed a workflow that allows a more precise and accurate quantification of soluble BCMA in plasma. The targeted MRM approach requires only a small volume of starting material and provides high sensitivity.